EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Liraglutide Modifies Gut Microbiota Without Modulating Doxorubicin-Induced Toxicity in Rats

Carolina R Tonon iD, Marina G Monte iD, Paola S Ballin iD, Anderson S S Fujimori iD, Natália F Ferreira, Nayane M Vieira, Lara P Carreira iD, Maria A M Rodrigues, Josias Rodrigues iD, Luiz Almeida Junior, Luiz C Di Stasi iD, Andrey Santos und 6 weitere

Antioxidants · 24.04.2026 · 15 (5) · 538

DOI: 10.3390/antiox15050538 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antioxidants, online erschienen am 24.04.2026. Verfasst von Carolina R Tonon und 17 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Botucatu Medical School, São Paulo State University (UNESP), Botucatu 18618-687, Brazil. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, National Council for Scientific and Technological Development, Fundação de Amparo à Pesquisa do Estado de São Paulo, FAPESP.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Doxorubicin is an effective chemotherapeutic agent, but it causes gastrointestinal toxicity that impairs treatment efficacy and quality of life. This study investigated the effects of liraglutide, a GLP-1 analog, on acute doxorubicin-induced gut toxicity in rats. Sixty male Wistar rats were assigned to four groups: Control (C), Doxorubicin (D), Liraglutide (L), and Doxorubicin + Liraglutide (DL). Groups L and DL received liraglutide (0.6 mg/kg, s.c.) for two weeks. D and DL were given a single dose of doxorubicin (20 mg/kg, i.p). After 48 h, the distal colon, feces, and blood were collected. Results: Doxorubicin caused crypt disruption, goblet cell loss, apoptosis, and reduced fecal short-chain fatty acids. Levels of TNF-α, NF-κB, Bcl-2, TLR4, and antioxidant enzymes were unchanged among groups. Microbiota analysis showed similar α-diversity but altered β-diversity. Doxorubicin reduced Bacteroidetes and increased Proteobacteria, with higher Arcanobacterium and Clavibacter genera abundance. Liraglutide alone decreased Bacteroidetes and increased Corynebacterium and Actinobaculum genera. Combined treatment showed no significant effects. We conclude that acute doxorubicin administration induces intestinal structural damage, reduces short-chain fatty acids, and changes microbiota composition. Although liraglutide alters microbial profiles, it does not attenuate doxorubicin-induced gut toxicity.

Schlagwörter

Stichwörter der Autor:innen

GLP-1doxorubicingut microbiotaintestinal toxicityshort-chain fatty acids

Autor:innen und Institutionen

  • Internal Medicine Department, Botucatu Medical School, São Paulo State University (UNESP), Botucatu 18618-687, Brazil.
  • Pathology Department, Botucatu Medical School, São Paulo State University (UNESP), Botucatu 18618-687, Brazil.
  • Laboratory of Medical Bacteriology, Department of Microbiology and Immunology, Institute of Biosciences, São Paulo State University (UNESP), Botucatu 18618-689, Brazil.
  • Laboratory of Phytomedicines, Pharmacology and Biotechnology (PhytoPharmaTech), Department of Biophysics and Pharmacology, Institute of Biosciences, São Paulo State University (UNESP), Botucatu 18618-689, Brazil.
  • Faculty of Medical Science, State University of Campinas (UNICAMP), Campinas 13083-894, Brazil.

ORCID-Profile: Carolina R Tonon, Marina G Monte, Paola S Ballin, Anderson S S Fujimori, Lara P Carreira, Josias Rodrigues, Luiz C Di Stasi, Daniela O Magro, Marina P Okoshi, Sergio A R Paiva, Bertha F Polegato

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • National Council for Scientific and Technological Development
  • Fundação de Amparo à Pesquisa do Estado de São Paulo, FAPESP
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq

Zitieren

APA

Tonon, C. R., Monte, M. G., Ballin, P. S., Fujimori, A. S. S., Ferreira, N. F., Vieira, N. M., Carreira, L. P., Rodrigues, M. A. M., Rodrigues, J., Almeida Junior, L., Di Stasi, L. C., Santos, A., Magro, D. O., Minicucci, M. F., Zornoff, L. A. M., Okoshi, M. P., Paiva, S. A. R., & Polegato, B. F. (2026). Liraglutide Modifies Gut Microbiota Without Modulating Doxorubicin-Induced Toxicity in Rats. Antioxidants, 15(5), 538. https://doi.org/10.3390/antiox15050538

Vancouver

Tonon CR, Monte MG, Ballin PS, Fujimori ASS, Ferreira NF, Vieira NM, et al. Liraglutide Modifies Gut Microbiota Without Modulating Doxorubicin-Induced Toxicity in Rats. Antioxidants. 2026;15(5):538. doi:10.3390/antiox15050538

BibTeX
@article{Tonon2026,
  author = {Tonon, Carolina R and Monte, Marina G and Ballin, Paola S and Fujimori, Anderson S S and Ferreira, Natália F and Vieira, Nayane M and Carreira, Lara P and Rodrigues, Maria A M and Rodrigues, Josias and Almeida Junior, Luiz and Di Stasi, Luiz C and Santos, Andrey and Magro, Daniela O and Minicucci, Marcos F and Zornoff, Leonardo A M and Okoshi, Marina P and Paiva, Sergio A R and Polegato, Bertha F},
  title = {Liraglutide Modifies Gut Microbiota Without Modulating Doxorubicin-Induced Toxicity in Rats},
  journal = {Antioxidants},
  year = {2026},
  volume = {15},
  number = {5},
  pages = {538},
  doi = {10.3390/antiox15050538}
}
Kostenlos starten →